title: ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
abstract: Cancer vaccines aim to induce CTL responses against tumors. Challenges for vaccine design are targeting Ag to dendritic cells (DCs) in vivo, facilitating cross-presentation, and conditioning the microenvironment for Th1 type immune responses. In this study, we report that ISCOM vaccines, which consist of ISCOMATRIX adjuvant and protein Ag, meet these challenges. Subcutaneous injection of an ISCOM vaccine in mice led to a substantial influx and activation of innate and adaptive immune effector cells in vaccine site-draining lymph nodes (VDLNs) as well as IFN-γ production by NK and NKT cells. Moreover, an ISCOM vaccine containing the model Ag OVA (OVA/ISCOM vaccine) was efficiently taken up by CD8α(+) DCs in VDLNs and induced their maturation and IL-12 production. Adoptive transfer of transgenic OT-I T cells revealed highly efficient cross-presentation of the OVA/ISCOM vaccine in vivo, whereas cross-presentation of soluble OVA was poor even at a 100-fold higher concentration. Cross-presenting activity was restricted to CD8α(+) DCs in VDLNs, whereas Langerin(+) DCs and CD8α(-) DCs were dispensable. Remarkably, compared with other adjuvant systems, the OVA/ISCOM vaccine induced a high frequency of OVA-specific CTLs capable of tumor cell killing in different tumor models. Thus, ISCOM vaccines combine potent immune activation with Ag delivery to CD8α(+) DCs in vivo for efficient induction of CTL responses.
authors: Medizinische Klinik Innenstadt, Ludwig-Maximilians-Universität, 80336 Munich, Germany.
authors: Peter
authors: P
authors: Duewell
authors: Ulrich
authors: U
authors: Kisser
authors: Klaus
authors: K
authors: Heckelsmiller
authors: Sabine
authors: S
authors: Hoves
authors: Patrizia
authors: P
authors: Stoitzner
authors: Sandra
authors: S
authors: Koernig
authors: Adriana B
authors: AB
authors: Morelli
authors: Björn E
authors: BE
authors: Clausen
authors: Marc
authors: M
authors: Dauer
authors: Andreas
authors: A
authors: Eigler
authors: David
authors: D
authors: Anz
authors: Carole
authors: C
authors: Bourquin
authors: Eugene
authors: E
authors: Maraskovsky
authors: Stefan
authors: S
authors: Endres
authors: Max
authors: M
authors: Schnurr
references: Nat Rev Immunol. 2006 Mar;6(3):173-82
references: 16498448
references: Nat Immunol. 2004 Jan;5(1):7-10
references: 14699398
references: Nat Rev Immunol. 2007 Oct;7(10):790-802
references: 17853902
references: J Exp Med. 2001 Jan 15;193(2):233-8
references: 11208863
references: J Immunol. 2009 Feb 1;182(3):1253-9
references: 19155470
references: Cancer Res. 2003 Jan 1;63(1):12-7
references: 12517769
references: Eur J Immunol. 2008 Feb;38(2):437-47
references: 18203135
references: Semin Immunol. 2005 Aug;17(4):262-72
references: 15946854
references: Cancer Res. 2005 Aug 1;65(15):7007-12
references: 16061687
references: J Exp Med. 1996 Aug 1;184(2):747-52
references: 8760829
references: Blood. 2003 Sep 15;102(6):2187-94
references: 12791652
references: Cancer Res. 2001 Jan 1;61(1):197-205
references: 11196161
references: Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10629-34
references: 12138174
references: J Cell Biol. 2005 May 23;169(4):569-76
references: 15897263
references: J Exp Med. 2002 Dec 16;196(12):1627-38
references: 12486105
references: Curr Opin Immunol. 2005 Feb;17(1):18-24
references: 15653305
references: Nature. 1984 Mar 29-Apr 4;308(5958):457-60
references: 6709052
references: J Invest Dermatol. 2010 Dec;130(12):2752-9
references: 20703247
references: J Immunol. 2000 Oct 15;165(8):4581-91
references: 11035100
references: Clin Cancer Res. 2004 Apr 15;10(8):2879-90
references: 15102697
references: Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702
references: 15252201
references: Blood. 2005 Mar 15;105(6):2465-72
references: 15546948
references: J Exp Med. 2002 Feb 4;195(3):327-33
references: 11828007
references: Immunity. 2002 Aug;17(2):211-20
references: 12196292
references: Annu Rev Immunol. 2009;27:229-65
references: 19302040
references: Vaccine. 2000 Oct 15;19(4-5):572-8
references: 11027823
references: Nat Med. 1999 Apr;5(4):405-11
references: 10202929
references: Int J Cancer. 2011 Feb 15;128(4):897-907
references: 20473889
references: Curr Opin Immunol. 2003 Apr;15(2):138-47
references: 12633662
references: J Immunol Methods. 2004 Feb 1;285(1):25-40
references: 14871532
references: J Exp Med. 2005 Apr 18;201(8):1281-92
references: 15837813
references: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7783-8
references: 16672373
references: Curr Opin Immunol. 2010 Feb;22(1):137-44
references: 20116984
references: J Immunol. 2004 Aug 1;173(3):1994-2002
references: 15265934
references: Expert Rev Vaccines. 2007 Oct;6(5):761-72
references: 17931156
references: Science. 2003 Sep 26;301(5641):1925-8
references: 14512632
references: Nature. 2007 Sep 27;449(7161):419-26
references: 17898760